Association Between Second-Generation Antipsychotics and Changes in Body Mass Index in Adolescents

作者：Ghate Sameer R^*; Porucznik Christina A; Said Qayyim; Hashibe Mia; Joy Elizabeth; Brixner Diana I

来源：Journal of Adolescent Health, 2013, 52(3): 336-343.

DOI：10.1016/j.jadohealth.2012.10.272

• Adolescents
• BMI
• Second generation antipsychotics
• Weight gain

Purpose: To assess the association of second generation antipsychotics (SGAs) with changes in body mass index (BMI) among adolescents compared with a matched untreated comparison group. %26lt;br%26gt;Methods: A retrospective cohort study was conducted using an electronic medical record database between January 2004 and July 2009. Adolescents (12-19 years old), newly initiated on SGAs formed the exposure group and untreated adolescents formed the comparison group matched (3: 1) to the antipsychotic group based on age, gender, and month of index SGA. Both the exposure and comparison groups were followed for slightly more than a year (395 days). Baseline and follow up BMI were evaluated for both groups and percentage change from baseline BMI to follow up BMI was calculated. Multivariate linear regression was conducted to assess the impact of SGAs on percent change in follow up BMI from baseline controlling for demographic characteristics, baseline medications, comorbidities, and other covariates. %26lt;br%26gt;Results: The mean percentage increase in follow up BMI from baseline for antipsychotic group was significantly higher than the comparison group (p %26lt; .01). After adjusting for covariates, adolescents on olanzapine had the highest percentage increase in follow up BMI from baseline (5.84%, 95% confidence interval [CI], 4.07-7.61) followed by aripiprazole (4.36%; 95% CI, 3.08-5.64), risper idone (3.65%; 95% CI, 2.61-4.68), and quetiapine (1.53%; 95% CI, .53-2.52) compared with the comparison group. %26lt;br%26gt;Conclusion: This study further validates a growing concern of increased BMI in adolescents on SGA therapy.

• 出版日期2013-3